Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE HYDROCHLORIDE vs Enoxaparin
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) in combination with aspirin,Prophylaxis of ischemic complications in patients with acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life is 4.5 hours after a single subcutaneous dose, and 7 hours after repeated dosing, reflecting accumulation. Mean half-life is approximately 4-5 hours in healthy volunteers.
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Enoxaparin is primarily metabolized in the liver by desulfation and depolymerization; elimination is via renal excretion of low molecular weight fragments.
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
Renal elimination accounts for 40% of the administered dose, with the remainder undergoing hepatic metabolism and/or distribution. Biliary/fecal excretion is minimal (<5%).
Approximately 50% bound to plasma proteins, primarily albumin.
Enoxaparin is highly protein bound (>80%) to antithrombin III and other plasma proteins.
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
Volume of distribution is approximately 0.15-0.25 L/kg (4-6 L total), indicating limited extravascular distribution, primarily confined to the vascular compartment.
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
Subcutaneous: Approximately 92-100% bioavailability based on anti-Xa activity. Oral: negligible due to poor absorption.
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis, reduce to 30 mg subcutaneously once daily.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
For treatment of venous thromboembolism: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Dose adjustments based on anti-Xa monitoring.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Increased risk of bleeding; consider lower initial doses and monitor renal function and bleeding closely. No specific dose adjustment solely based on age.
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Spinal or epidural hematomas, including subsequent paralysis, may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture. Risk is increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural or spinal puncture, or spinal deformity.
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Increased risk of bleeding, especially in patients with renal impairment, uncontrolled hypertension, or history of gastrointestinal bleeding; thrombocytopenia (including heparin-induced thrombocytopenia); elevated serum potassium levels (hyperkalemia); use in pregnancy and lactation; elderly patients (increased bleeding risk).
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
Active major bleeding; history of heparin-induced thrombocytopenia (HIT); hypersensitivity to enoxaparin or heparin; patients undergoing regional anesthesia with known bleeding risk; severe uncontrolled hypertension; bacterial endocarditis; conditions with increased risk of hemorrhage (e.g., recent surgery, trauma, peptic ulcer disease, hemorrhagic stroke).
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
No specific food interactions. Vitamin K-rich foods (leafy greens) do not significantly affect LMWH, in contrast to warfarin. Avoid excessive alcohol intake due to increased bleeding risk. Do not take supplements like fish oil, ginkgo, or ginger without consulting prescriber due to antiplatelet effects.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second and third trimesters: no known risk, though there is a risk of maternal hemorrhage that could affect the fetus.
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
Enoxaparin is not detected in breast milk due to its high molecular weight and protein binding; therefore, it is considered compatible with breastfeeding. M/P ratio: not applicable (not measurable).
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
Pregnancy increases clearance of enoxaparin; dose adjustments may be needed based on anti-Xa monitoring. Generally, dose adjustments are not routinely required for standard prophylactic doses, but therapeutic doses may need to be increased (e.g., weight-based dosing) and monitored. Avoid use in patients with active major bleeding or known hypersensitivity.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-factor Xa levels in patients with renal impairment (Cr Cl <30 m L/min) and in pregnant women. Protamine sulfate partially reverses anticoagulation (approximately 60% anti-factor Xa activity). Avoid intramuscular injections due to hematoma risk. Epidural/spinal anesthesia increases risk of spinal hematoma; remove catheter at least 12 hours after last dose (or 24 hours if therapeutic dosing). Adjust dose for moderate renal impairment (Cr Cl 30-50 m L/min) in treatment of VTE or unstable angina.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
Do not skip doses; take at the same time each day.,Rotate injection sites (left and right sides of abdomen) and do not rub the site after injection.,Watch for signs of bleeding: unusual bruising, blood in urine/stool, prolonged bleeding from cuts, or bleeding from gums.,Seek emergency care if you have signs of a spinal blood clot (back pain, numbness/weakness in legs, loss of bowel or bladder control).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), and other blood thinners unless prescribed by your doctor.,Tell all healthcare providers including dentists that you are taking enoxaparin.,Do not drive or operate heavy machinery if you feel dizzy or weak from bleeding.,Store enoxaparin at room temperature; do not freeze.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE HYDROCHLORIDE vs Enoxaparin, answered by our medical review team.
NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. Enoxaparin is a Low Molecular Weight Heparin that works by Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE HYDROCHLORIDE and Enoxaparin depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of Enoxaparin is: 1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE HYDROCHLORIDE and Enoxaparin in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. Enoxaparin is classified as Category A/B. Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.